title: FDA-approved drug labeling for the study of drug-induced liver injury.
abstract: Drug-induced liver injury (DILI) is a leading cause of drugs failing during clinical trials and being withdrawn from the market. Comparative analysis of drugs based on their DILI potential is an effective approach to discover key DILI mechanisms and risk factors. However, assessing the DILI potential of a drug is a challenge with no existing consensus methods. We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts. The method is transparent and reproducible with a potential to serve as a common practice to study the DILI of marketed drugs for supporting drug discovery and biomarker development.
authors.affiliation: Division of Systems Biology, National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, Jefferson, AR 72079, USA.
authors.forename: Minjun
authors.initials: M
authors.lastname: Chen
authors.forename: Vikrant
authors.initials: V
authors.lastname: Vijay
authors.forename: Qiang
authors.initials: Q
authors.lastname: Shi
authors.forename: Zhichao
authors.initials: Z
authors.lastname: Liu
authors.forename: Hong
authors.initials: H
authors.lastname: Fang
authors.forename: Weida
authors.initials: W
authors.lastname: Tong
mesh_terms: D000818:Animals; D019985:Benchmarking; D054316:Biomarkers, Pharmacological / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D015195:Drug Design; D004348:Drug Labeling; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D004364:Pharmaceutical Preparations / Q000145:classification; D015203:Reproducibility of Results; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D054316:Biomarkers, Pharmacological; D004364:Pharmaceutical Preparations